SYS-CON MEDIA Authors: Bob Gourley, Sandi Mappic, Eric Brown, RealWire News Distribution, Kevin Benedict

News Feed Item

Investigation Report on China Budesonide Market

DUBLIN, March 25, 2014 /PRNewswire/ --

Research  and  Markets (http://www.researchandmarkets.com/research/s3kv36/investigation) has announced the addition of the "Investigation Report on China Budesonide Market" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere becomes more and more seriously contaminated, incidence of these diseases increases year by year. 

Budesonide inhalation suspension (trade name ""Pulmicort Respules"") developed by Astra Zeneca was approved to market by FDA for asthma treatment in August 2000. It obtained import approval in China in November 2001. Statistics shows that there are more than 30 million asthma patients and over 0.3 billion people suffering from allergic rhinitis in China. According to CRI's investigation on certain sample hospital market in China, the CAGR of sales value of budesonide surpassed 30% from 2005 to 2010. Since 2011, market growth has slowed down, but it still maintains an annual growth rate of 18%. 

In April 2013, the patent protection of asthma drug ""Pulmicort Respules"" produced by Astra Zeneca was sentenced invalid in an U.S. regional court. Industry insiders think that this has paved the way for generic drug to occupy the market. 

According to CRI's market investigation, budesonide products in Chinese market are still mainly imported drugs from Astra Zeneca, but there are already some Chinese enterprises, such as Lunan Better Pharmaceutical Co., Ltd., Humanwell Healthcare (Group) Co., Ltd. and Shanghai Sine Promod Pharmaceutical Co., Ltd., producing budesonide APIs and finished drugs. 

On January 15, 2013 Santarus, Inc. announced that FDA has ratifies the usage of Uceris sustained release tablets in alleviating symptoms of mild - moderate active ulcerative colitis. Uceris is a new drug developed by Santarus, Inc. and Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A. This is a new oral tablet, and its main ingredient is budesonide. 

As Chinese economy develops and its environment worsens, the number of asthma and allergic rhinitis patients in China will continue to rise in the next few years. Furthermore, more indications may emerge in China. Consequently, market size of budesonide in China will therefore continue to grow. 


Key  Topics  Covered: 

1 Relevant Concepts of Budesonide

2 Market Overview of Budesonide in China

3 Investigation on Sales Value of Budesonide in China, 2009-2013

4 Investigation on Market Share of Major Budesonide Manufacturers in China, 2009-2013

5 Investigation on Market Size of Budesonide by Dosage Form in China, 2009-2013

6 Reference Price of Budesonide Produced by Different Enterprises in China Hospital Market, 2013

7 Analysis on Major Budesonide Manufacturers in China, 2009-2013

8 Prospect of China Budesonide Market, 2014-2018


Companies  Mentioned:

  • AstraZeneca Australia
  • AstraZeneca plc.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Synmosa Biopharma Corp.


For more information visit http://www.researchandmarkets.com/research/s3kv36/investigation


Media  Contact: Laura Wood , +353-1-481-1716, [email protected]


SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.